DuChemBIO Co.,Ltd. (KOSDAQ:176750)

Market Cap	256.24B -25.7%
Revenue (ttm)	38.57B +8.3%
Net Income	6.48B -18.9%
EPS	228.00 -23.4%
Shares Out	28.34M
PE Ratio	39.65
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,986
Average Volume	25,773
Open	9,180.00
Previous Close	9,120.00
Day's Range	8,960.00 - 9,180.00
52-Week Range	8,360.00 - 12,770.00
Beta	0.18
RSI	46.19
Earnings Date	May 13, 2026

About DuChemBIO

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amylo...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2002
• Employees: 126
• Stock Exchange: KOSDAQ
• Ticker Symbol: 176750

Financial Performance

In 2025, DuChemBIO's revenue was 38.57 billion, an increase of 8.35% compared to the previous year's 35.60 billion. Earnings were 6.48 billion, a decrease of -18.94%.